Publication

Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature

Leus, A. J. G., Frie, M., Haisma, M. S., Terra, J. B., Plaat, B. E. C., Steenbakkers, R. J. H. M., Halmos, G. B. & Rácz, E., 6-Feb-2020, In : Journal of the European Academy of Dermatology and Venereology. 9, p. 1932-1943 12 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Leus, A. J. G., Frie, M., Haisma, M. S., Terra, J. B., Plaat, B. E. C., Steenbakkers, R. J. H. M., Halmos, G. B., & Rácz, E. (2020). Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature. Journal of the European Academy of Dermatology and Venereology, (9), 1932-1943. https://doi.org/10.1111/jdv.16268

Author

Leus, A J G ; Frie, M ; Haisma, M S ; Terra, J B ; Plaat, B E C ; Steenbakkers, R J H M ; Halmos, G B ; Rácz, E. / Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature. In: Journal of the European Academy of Dermatology and Venereology. 2020 ; No. 9. pp. 1932-1943.

Harvard

Leus, AJG, Frie, M, Haisma, MS, Terra, JB, Plaat, BEC, Steenbakkers, RJHM, Halmos, GB & Rácz, E 2020, 'Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature', Journal of the European Academy of Dermatology and Venereology, no. 9, pp. 1932-1943. https://doi.org/10.1111/jdv.16268

Standard

Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature. / Leus, A J G; Frie, M; Haisma, M S; Terra, J B; Plaat, B E C; Steenbakkers, R J H M; Halmos, G B; Rácz, E.

In: Journal of the European Academy of Dermatology and Venereology, No. 9, 06.02.2020, p. 1932-1943.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Leus AJG, Frie M, Haisma MS, Terra JB, Plaat BEC, Steenbakkers RJHM et al. Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature. Journal of the European Academy of Dermatology and Venereology. 2020 Feb 6;(9):1932-1943. https://doi.org/10.1111/jdv.16268


BibTeX

@article{c696d1c443aa47468b45ae3f48b33657,
title = "Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature",
abstract = "A large percentage of the patients with keratinocyte carcinoma (KC, formerly known as non-melanoma skin cancer) is of advanced age and often too frail for standard therapies. However, no specific treatment recommendations are given for this population. This review aimed to give an overview of the current literature on the best practice for the treatment of elderly patients with KC. A literature search was performed in MEDLINE, using {\textquoteleft}keratinocyte carcinoma{\textquoteright}, {\textquoteleft}elderly{\textquoteright}, {\textquoteleft}treatment{\textquoteright} and various synonyms. Case reports, reviews, comments, non-English literature and studies with a sample size <15 were excluded. After selection, a total of 47 studies were reviewed. Two types of studies were identified, focusing on (I) the effect of age on treatment outcomes and (II) alternative treatment schedules for elderly patients. Studies on surgery, the gold standard, describe larger lesions and defect size in the elderly population. Recurrence rate, complication rate and disease-specific survival were not affected by age. Depending on the expected morbidity of a suggested (re-)excision and patient preferences, a conservative watchful waiting policy can be agreed upon as a shared decision. Other common treatment modalities, such as adjuvant radiotherapy, photodynamic therapy and systemic therapy for basal cell carcinoma (BCC), show comparable results in the elderly and younger population. Alternative treatment schedules for elderly patients include primary hypofractionated radiotherapy, which seems effective and well-tolerated, although research is limited to case series. Additionally, localized and topical treatments seem safe and effective especially for low-risk tumours. Data are lacking on the efficacy of systemic therapies of metastatic KC in elderly patients. Efficacy of most treatments (with the exception of photodynamic therapy) is not dependent on age. There is need for more research on the efficacy of adjusted treatment modalities, such as hypofractionated radiotherapy and palliative or curative systemic treatment.",
author = "Leus, {A J G} and M Frie and Haisma, {M S} and Terra, {J B} and Plaat, {B E C} and Steenbakkers, {R J H M} and Halmos, {G B} and E R{\'a}cz",
note = "This article is protected by copyright. All rights reserved.",
year = "2020",
month = feb,
day = "6",
doi = "10.1111/jdv.16268",
language = "English",
pages = "1932--1943",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley",
number = "9",

}

RIS

TY - JOUR

T1 - Treatment of keratinocyte carcinoma in elderly patients - a review of the current literature

AU - Leus, A J G

AU - Frie, M

AU - Haisma, M S

AU - Terra, J B

AU - Plaat, B E C

AU - Steenbakkers, R J H M

AU - Halmos, G B

AU - Rácz, E

N1 - This article is protected by copyright. All rights reserved.

PY - 2020/2/6

Y1 - 2020/2/6

N2 - A large percentage of the patients with keratinocyte carcinoma (KC, formerly known as non-melanoma skin cancer) is of advanced age and often too frail for standard therapies. However, no specific treatment recommendations are given for this population. This review aimed to give an overview of the current literature on the best practice for the treatment of elderly patients with KC. A literature search was performed in MEDLINE, using ‘keratinocyte carcinoma’, ‘elderly’, ‘treatment’ and various synonyms. Case reports, reviews, comments, non-English literature and studies with a sample size <15 were excluded. After selection, a total of 47 studies were reviewed. Two types of studies were identified, focusing on (I) the effect of age on treatment outcomes and (II) alternative treatment schedules for elderly patients. Studies on surgery, the gold standard, describe larger lesions and defect size in the elderly population. Recurrence rate, complication rate and disease-specific survival were not affected by age. Depending on the expected morbidity of a suggested (re-)excision and patient preferences, a conservative watchful waiting policy can be agreed upon as a shared decision. Other common treatment modalities, such as adjuvant radiotherapy, photodynamic therapy and systemic therapy for basal cell carcinoma (BCC), show comparable results in the elderly and younger population. Alternative treatment schedules for elderly patients include primary hypofractionated radiotherapy, which seems effective and well-tolerated, although research is limited to case series. Additionally, localized and topical treatments seem safe and effective especially for low-risk tumours. Data are lacking on the efficacy of systemic therapies of metastatic KC in elderly patients. Efficacy of most treatments (with the exception of photodynamic therapy) is not dependent on age. There is need for more research on the efficacy of adjusted treatment modalities, such as hypofractionated radiotherapy and palliative or curative systemic treatment.

AB - A large percentage of the patients with keratinocyte carcinoma (KC, formerly known as non-melanoma skin cancer) is of advanced age and often too frail for standard therapies. However, no specific treatment recommendations are given for this population. This review aimed to give an overview of the current literature on the best practice for the treatment of elderly patients with KC. A literature search was performed in MEDLINE, using ‘keratinocyte carcinoma’, ‘elderly’, ‘treatment’ and various synonyms. Case reports, reviews, comments, non-English literature and studies with a sample size <15 were excluded. After selection, a total of 47 studies were reviewed. Two types of studies were identified, focusing on (I) the effect of age on treatment outcomes and (II) alternative treatment schedules for elderly patients. Studies on surgery, the gold standard, describe larger lesions and defect size in the elderly population. Recurrence rate, complication rate and disease-specific survival were not affected by age. Depending on the expected morbidity of a suggested (re-)excision and patient preferences, a conservative watchful waiting policy can be agreed upon as a shared decision. Other common treatment modalities, such as adjuvant radiotherapy, photodynamic therapy and systemic therapy for basal cell carcinoma (BCC), show comparable results in the elderly and younger population. Alternative treatment schedules for elderly patients include primary hypofractionated radiotherapy, which seems effective and well-tolerated, although research is limited to case series. Additionally, localized and topical treatments seem safe and effective especially for low-risk tumours. Data are lacking on the efficacy of systemic therapies of metastatic KC in elderly patients. Efficacy of most treatments (with the exception of photodynamic therapy) is not dependent on age. There is need for more research on the efficacy of adjusted treatment modalities, such as hypofractionated radiotherapy and palliative or curative systemic treatment.

U2 - 10.1111/jdv.16268

DO - 10.1111/jdv.16268

M3 - Review article

C2 - 32030838

SP - 1932

EP - 1943

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 9

ER -

ID: 118328418